Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b conjugate vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Infanrix Polio + Hib (also known as Infanrix-IPV+Hib) is a pentavalent combination vaccine developed by GSK (GlaxoSmithKline) Biologicals. It is designed for active immunization in infants and young children against five major infectious diseases: diphtheria, tetanus, pertussis (whooping cough), poliomyelitis (polio), and invasive diseases caused by Haemophilus influenzae type b (Hib). The vaccine is formulated as a suspension for deep intramuscular injection and contains diphtheria toxoid, tetanus toxoid, three purified acellular pertussis antigens (pertussis toxoid, filamentous hemagglutinin, and pertactin) adsorbed onto aluminum salts, inactivated poliovirus types 1, 2, and 3, and purified polyribosyl-ribitol-phosphate (PRP) capsular polysaccharide of Hib conjugated to tetanus toxoid. In clinical trials, such as those sponsored by Örebro Läns Landsting in Sweden, Infanrix Polio + Hib has also been evaluated for re-immunization of patients who have lost vaccine-acquired immunity following autologous or allogeneic hematopoietic stem cell transplantation.
- Brand names
- Infanrix Polio + HibInfanrix-IPV+HibInfanrix-IPV/HibInfanrix Polio HibInfanrix IPV-HibInfanrix IPV + Hib
- Other names
- diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b conjugate vaccineDTPa-IPV/Hib vaccineDTaP-IPV-Hib vaccinepentavalent DTaP-IPV/Hib vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b conjugate vaccine.